Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy

doi:10.12998/wjcc.v10.i19.6555

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3489)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

217

WORD

HTML

1811

Figures (1-4)

300

Tables (1-1)

364

Sum=2736

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

255

Download

498

Sum=753

Jul 6, 2022 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jul 6, 2022; 10(19): 6555-6562
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6555

Full Size Figure Download Figure

Figure 3 Treatment response of each patient and the duration of response after treatment with sintilimab and chidamide.

Citation: Hao YY, Chen PP, Yuan XG, Zhao AQ, Liang Y, Liu H, Qian WB. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. World J Clin Cases 2022; 10(19): 6555-6562
URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6555.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6555